share_log

HC Wainwright & Co. Initiates Coverage On NewAmsterdam Pharma With Buy Rating, Announces Price Target of $48

HC Wainwright & Co. Initiates Coverage On NewAmsterdam Pharma With Buy Rating, Announces Price Target of $48

HC Wainwright & Co. 对NewAmsterdam Pharma启动覆盖,给予买入评级,并宣布目标价格为48美元。
Benzinga ·  2024/12/30 07:03  · 评级/大行评级

HC Wainwright & Co. analyst Ed Arce initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Buy rating and announces Price Target of $48.

HC Wainwright & Co. 分析师 Ed Arce 对 NewAmsterdam Pharma (纳斯达克:NAMS) 进行覆盖评级,给予买入评级,并宣布目标价为48美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发